

AD-A160 141 MOLECULAR APPROACHES TO SELECTIVE IMMUNIZATION(U)
MINNESOTA UNIV MINNEAPOLIS F H BACH 30 SEP 85
N00014-85-K-0004


1/1

UNCLASSIFIED

F/G 6/1

NL





MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS - 1963 - A

AD-A160 141

DTIC FILE COPY

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) Molecular Approaches to Selective Immunization		5. TYPE OF REPORT & PERIOD COVERED FINAL REPORT 84OCT15 - 85JUL31
AUTHOR(s) Fritz H. Bach, M.D.		6. PERFORMING ORG. REPORT NUMBER N00014-85-K-0004
PERFORMING ORGANIZATION NAME AND ADDRESS Regents of the University of Minnesota (4G919) Box 724 Mayo Memorial Bldg., 420 Delaware St. SE Minneapolis, Minnesota 55455		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS NR 666-042/8-10-84 (440)
CONTROLLING OFFICE NAME AND ADDRESS Department of the Navy, Office of Naval Research (N00014) 800 North Quincy Street Arlington, Virginia 22217		12. REPORT DATE 09/30/85
11. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office) Office of Naval Research Resident Representative (N62880) Room 286, 536 South Clark Street Chicago, Illinois 60605		13. NUMBER OF PAGES
		15. SECURITY CLASS. (of this report)
		18a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report) Immunological Defense Program This document has been approved for public release and sale; its distribution is unlimited.		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report) Immunological Defense Program		
18. SUPPLEMENTARY NOTES Enclosed, in addition to final report, four manuscripts (in press): 1.) "Clonal Analysis of HLA-DR and -DQ associated determinants - their contribution to Dw specificities"; Reinsmoen, N.L., Bach, F.H. Hum. Immunol., 1985, in press. (cont.)		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) Class II molecules T lymphocyte recognition DNA sequence		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) The sequence polymorphism underlying T lymphocyte recognition as related to the DR alpha beta dimer has been studied using cDNA libraries. DR beta genes from homozygous typing cells expressing the same serologically-defined DR antigen but differing in their Dw subtype, have allowed the pinpointing of single amino acid differences underlying this allotypic variation in some combinations, and two to three amino acid differences in others.		

Block 18 (cont.)

2.) "DNA and protein studies of HLA class II molecules: their relationship to T cell recognition"; Segall,M., Cairns,J.S., Dahl,C.A., Curtsinger,J.M., Freeman,S., Nelson,P.J., Cohen,O., Wu,S., Nicklas,J.N., Noreen,H.J., Linner,K.M., Saunders,T.L., Choong,S.A., Ohta,N., Reinsmoen,N.L., Alter,B.J., and Bach,F.H.; Immunol. Rev.; In press.

3.) "HLA-D: The T cell perspective"; Bach,F.H., Ohta,N., Anichini,A., and Reinsmoen,N.L.; in: Human Class II Histocompatibility Antigens. (Eds: S.Ferrone, B.Solheim, E.Moller); Springer-Verlag. 1985, In press.

4.) "Sequence polymorphism of HLA-DR $\beta 1$ alleles relating to T cell-recognized determinants"; Cairns,S., Curtsinger,J.M., Dahl,C.A., Freeman,S., Alter,B.J., and Bach,F.H.; Nature, In press.

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	<i>PL</i>
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
<i>A-1</i>	



85 10 03 092

S/N 0102-LF-014-6601

The goals for the contract referenced above were to establish cDNA cloning and sequencing technology that would permit evaluation of sequences from cells differing by certain well-designated Dw specificities on homozygous typing cells (HTCs). The specific scientific question to be answered was to evaluate DNA sequence variation that existed between alleles of a DR β locus (known to be polymorphic) among HTCs that all express the same serologically-defined specificity, but that differed with regard to the specificities recognized by T cells, i.e. defined by HTCs in the primary mixed leukocyte culture (MLC). It was reasoned in the application that differences between such HTCs might be of a lesser extent than those found between DR β sequences from cells expressing different serologically-defined DR antigens, and that this lesser polymorphism might be, thus, more readily related to the sequence variation underlying T cell recognition.

One difficulty that potentially existed in the proposed studies was to differentiate between the two DR β genes that can be expressed in DR4 haplotypes, the particular haplotype that we proposed for study. These are referred to as DR β_1 and DR β_2 . It is known that the DR β_2 gene is relatively invariant. Fortunately, based on a number of different lines of investigation, we were able to conclude that alleles we studied were alleles of the DR β_1 locus, the polymorphic locus thought to encode not only the allelism encoding the serologically-defined DR specificities, but also that carrying much of the polymorphism seen by T lymphocytes.

Our results fully answered the first, and fundamental question that we posed for the contract. Namely, we were able to define three alleles of the DR β_1 locus present in HTCs, all of which type as DR4 but express different Dw specificities subtypic to DR4, Dw4, Dw13, and Dw14. Since the differences between alleles were minimal, certain conclusions can be reached for some comparisons.

We used cloning into pUC 9 and sequencing by the dideoxy method. As a modification, we used the sub-cloning technique of Dale and co-workers.

Assignment of our sequences to DR β_1 was based largely on sequences obtained by Spies and co-workers (see reprint attached) at the genomic level, in which they were able to clearly identify DR β_1 and DR β_2 since they were able to compare the DNA sequences with the N-terminal sequences obtained in proteins isolated with antibodies of known β_1 or β_2 specificity. Our sequences were clearly more closely related to the DR β_1 sequence.

We were able to sequence 2 DR β_1 genes, one from an HTC-expressing DR4-Dw14, and one from an HTC-expressing DR4-Dw13. In addition, we were able to identify, using cloned cytotoxic T lymphocytes, the DR components of an HLA haplotype in an HLA heterozygous cell from which Long and co-workers isolated and sequenced a DR β gene. We identified this haplotype as having components of Dw4 and, based on sequence comparisons with the genes that we sequenced, we were able to assign the sequence obtained by Long to the DR β_1 locus as well.

The results, now published in Nature, demonstrate that the three sequences, i.e. from Dw4, Dw13, and Dw14, differ by between 1 and 3 amino acids at amino acid positions 71, 74, and 86. These are, thus, in the N-terminal domain. The sequences for Dw14 and Dw13 are given in the attached reprint. As can be seen, these two sequences differ for only a single base pair substitution that results in a glutamic acid at position 74 in Dw13, and an alanine at the same position in Dw14. The Dw4 sequence of Long and co-workers differs from those obtained by us for Dw13 and Dw14 due to a lysine at amino acid 71 (instead of the arginine present in the Dw14 and Dw13 sequences) and a glycine at position 86 (instead of the valine present in Dw13 and Dw14).

We thus feel we have answered the questions that were posed in the contract.

DISTRIBUTION LIST

Immunological Defense Program

Annual, Final and Technical Reports (one copy each except as noted)

Fritz H. Bach, M.D.
Director, Immunology Research Center
University of Minnesota
Box 724, Mayo Memorial Bldg.
420 Delaware St., SE
Minneapolis, MN 55455

Francis A. Ennis, M.D.
Department of Medicine
University of Massachusetts
Medical School
55 Lake Avenue
Worcester, MA 01605

Fred D. Finkelman, M.D.
Department of Medicine
Uniformed Services University
of the Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814

Dr. Matthew J. Kluger
Department of Physiology
University of Michigan Med. School
7620 Medical Science II Bldg.
Ann Arbor, MI 48109

Dr. Vijaya Manohar
Borriston Laboratories, Inc.
5050 Beech Place
Temple Hills, MD 20748

Dr. Ernest D. Marquez
Bioassay Systems Corporation
225 Wildwood Avenue
Woburn, MA 01801

James J. Mond, M.D.
Department of Medicine
Uniformed Services University
of the Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814

Dr. Donna S. Sieckmann
Infectious Diseases Program Center
Naval Medical Research Inst.
National Naval Medical Center
Bethesda, MD 20814

Dr. John D. Clements
Department of Microbiology
and Immunology
Tulane University Medical Ctr.
1430 Tulane Avenue
New Orleans, LA 70112

Dr. Edward A. Havell
Trudeau Institute
P.O. Box 59
Saranac Lake, NY 12983

Dr. Arthur G. Johnson
Department of Medical
Microbiology and Immunology
University of Minnesota
School of Medicine
2205 East 5th Street
Duluth, MN 55812

Dr. Philip Lake
Immunologic Oncology Division
Lombardy Cancer Center
Georgetown Univ. School of Med.
Washington, DC 20007

W. John Martin, M.D., Ph.D.
Laboratory, Dept. of Medicine
Naval Hospital
National Naval Medical Center
Bethesda, MD 20814

Dr. Robert I. Mishell
Dept. of Microbiology &
Immunology
Univ. of California, Berkeley
Berkeley, CA 94720

Dr. Page S. Morahan
Department of Microbiology
Medical College of Pennsylvania
3300 Henry Avenue
Philadelphia, PA 19129

Dr. Alan L. Schmaljohn
Department of Microbiology
University of Maryland
School of Medicine
660 W Redwood Street
Baltimore, MD 21201

Annual, Final and Technical Reports (one copy each except as noted)

Dr. Jeannine A. Majde, Code 441CB
Scientific Officer, Immunology Program
Office of Naval Research
800 N. Quincy Street
Arlington, VA 22217

Administrator (2 copies)
Defense Technical Information Center
Building 5, Cameron Station
Alexandria, VA 22314

Annual and Final Reports Only (one copy each)

Commanding Officer
Naval Medical Command
Washington, DC 20372

Commanding Officer
Naval Medical Research & Development Command
National Naval Medical Center
Bethesda, MD 20814

Director, Infectious Diseases Program Center
Naval Medical Research Institute
National Naval Medical Center
Bethesda, MD 20814

Commander
Chemical and Biological Sciences Division
Army Research Office, P. O. Box 12211
Research Triangle Park, NC 27709

Commander
U.S. Army Research and Development Command
Attn: SGRD-PLA
Fort Detrick
Frederick, MD 21701

Commander
USAMRIID
Fort Detrick
Frederick, MD 21701

Directorate of Life Sciences
Air Force Office of Scientific Research
Bolling Air Force Base
Washington, DC 20332

Administrative Contracting Officer
ONR Resident Representative
(address varies - obtain from Business Office)

Final and Technical Reports Only

Director, Naval Research Laboratory (6 copies)
Attn: Technical Information Division, Code 2627
Washington, DC 20375

Annual, Final and Technical Reports (Cont.)

David A. Stevens, M.D.
Department of Medicine
Santa Clara Valley Medical Center
Stanford University
751 S. Bascom Avenue
San Jose, CA 95128

Dr. Barnet M. Sultz
Department of Microbiology &
Immunology
Downstate Medical Center
450 Clarkson Avenue
Brooklyn, NY 11203

Dr. Alvin L. Winters
Department of Microbiology
University of Alabama
University, AL 35486

Dr. Phyllis R. Strauss
Department of Biology
Northeastern University
360 Huntington Avenue
Boston, MA 02115

G. Jeanette Thorbecke, M.D.
Department of Pathology
New York University
School of Medicine
550 First Avenue
New York, NY 10016

Lyn Yaffe, M.D.
Research Support Center
Naval Medical Research Inst.
National Naval Medical Center
Bethesda, MD 20814

END

FILMED

11-85

DTIC